A Phase I Trial of Doxorubicin, Paclitaxel, and Valspodar (PSC 833), a Modulator of Multidrug Resistance by ADVANI, Ranjana, FISHER, George A, LUM, Bert L, HAUSDORFF, John, HALSEY, Joanne, LITCHMAN, Manuel, SIKIC, Branimir I

Get full text

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL by Porter, David L., Kalos, Michael, Frey, Noelle V., Grupp, Stephan A, Loren, Alison W., Jemision, Christina, Gilmore, Joan, McConville, Holly, Capobianchi, James, Lledo, Lester, Chew, Anne, Shen, Angela, Wood, Patricia A., Litchman, Manuel, Zheng, Zhaohui, Levine, Bruce L., June, Carl H.

Get full text

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gv... by Grupp, Stephan A, Frey, Noelle V., Aplenc, Richard, Barrett, David M, Chew, Anne, Kalos, Michael, Levine, Bruce L., Litchman, Manuel, Maude, Shannon L, Rheingold, Susan R., Shen, Angela, Strait, Christine, Teachey, David T., Wood, Patricia A., Porter, David, June, Carl H.

Get full text

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas by Schuster, Stephen J., Svoboda, Jakub, Dwivedy Nasta, Sunita, Porter, David L., Chong, Elise A., Mahnke, Yolanda, Lacey, Simon F., Melenhorst, J. Joseph, Chew, Anne, Shah, Gaurav, Hasskarl, Jens, Litchman, Manuel, Wasik, Mariusz A., Landsburg, Daniel J., Mato, Anthony R., Garfall, Alfred L., Frey, Noelle V., Marcucci, Katherine T., Shea, Joanne, McConville, Holly, Zheng, Zhaohui, Levine, Bruce L., June, Carl H.

Get full text

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL by Porter, David L., Frey, Noelle V., Melenhorst, J. Joseph, Hwang, Wei-Ting, Lacey, Simon F., Shaw, Pamela, Chew, Anne, Grupp, Stephan A., Capobianchi, James, Gilmore, Joan, Kalos, Michael, Litchman, Manuel, Lledo, Lester, Loren, Alison Wakoff, Mahnke, Yolanda, Marcucci, Katherine T., McConville, Holly, Shen, Angela, Wood, Patricia A., Zheng, Zhaohui, Levine, Bruce L., June, Carl H.

Get full text

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL by Porter, David L., Lacey, Simon F., Hwang, Wei-Ting, Shaw, Pamela, Frey, Noelle V., Chew, Anne, Chen, Fang, Kalos, Michael, Gonzalez, Vanessa, Marcucci, Katherine T., Maude, Shannon L, Melenhorst, Jan J, Litchman, Manuel, Teachey, David T., Shen, Angela, Quintas-Cardamas, Alfonso, Wood, Patricia A., Levine, Bruce L., June, Carl H., Grupp, Stephan A.

Get full text

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar) by Advani, Ranjana, Saba, Hussain I., Tallman, Martin S., Rowe, Jacob M., Wiernik, Peter H., Ramek, Joseph, Dugan, Kathleen, Lum, Bert, Villena, Jenny, Davis, Eric, Paietta, Elisabeth, Litchman, Manuel, Sikic, Branimir I., Greenberg, Peter L.

Get full text

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar) by Advani, Ranjana, Saba, Hussain I., Tallman, Martin S., Rowe, Jacob M., Wiernik, Peter H., Ramek, Joseph, Dugan, Kathleen, Lum, Bert, Villena, Jenny, Davis, Eric, Paietta, Elisabeth, Litchman, Manuel, Sikic, Branimir I., Greenberg, Peter L.

Get full text

Ultraviolet index counseling as a primary prevention strategy by US dermatologists by Snyder, Alan N., Litchman, Graham H., Plante, John G., Valdebran, Manuel A., Rigel, Darrell S.

Get full text